Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Immune Killer Cells in Late Stage HCC or Lung Cancer
NCT03515252Phase 1Completed
- Sponsor
- Ivy Life Sciences
- Start
- Apr 2005
- Primary completion
- Nov 2006
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
01
Overview
Phase 1, open-label, single-arm trial of Immune Killer Cell in hepatocellular carcinoma (HCC) and non-small cell lung cancer (NSCLC), sponsored by Ivy Life Sciences. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 5 months. Started Apr 2005; status: completed.
02
Drugs
Immune Killer Cell
03
Conditions
hepatocellular carcinoma (HCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03515252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03515252.